TERMS OF CREDIT

Release Date: 12/31/2019
Expiration Date: 12/30/2020

ESTIMATED TIME TO COMPLETE

180 minutes

ACTIVITY OVERVIEW

This highly interactive ePrimer provides updates on MS pathophysiology and disease course, current and emerging disease modifying therapies (including recent developments in the treatment of progressive MS), and dimensions of health and wellness for patients with MS. As a result of the education, clinicians will advance their knowledge, increase their competence and adoption of state-of-the-art MS care.

COPYRIGHT STATEMENT

© 2018 The France Foundation.

GRANT STATEMENT

This activity is supported by educational grants from Abbvie, Biogen, Celgene and Sanofi Genzyme.

NEEDS ASSESSMENT

In light of the recent rapid pace of pharmacotherapy development and availability in MS, it becomes especially crucial that neurologists and other health care providers are well equipped to evaluate and apply data on the latest therapies to the complex task of initial and subsequent treatment selection. While the focus of the current clinical and research climate is often on newer therapies with innovative mechanisms, it remains important that neurologists and others remain up-to-date on data and options pertaining to established therapies as well. It is equally essential that clinicians are equipped with evidence-based knowledge and skills that facilitate timely and accurate evaluation of disease activity and progression, both clinically and radiologically, as a means of informing prognosis and optimal treatment selection. Finally, despite the proven benefit of comprehensive, coordinated care to patients, many clinicians still function in clinical “silos” instead of working seamlessly together to prevent a fragmented healthcare experience with little care coordination for the patient. All of these gaps present opportunities for ongoing education.

LEARNING OBJECTIVES

Upon completion of the activity, participants should be able to:

• Differentiate between key characteristics of newer (non-platform) MS therapies that should be considered when starting or switching treatment
• Decide to initiate or switch treatment based on relevant criteria
• Summarize new developments among platform therapies for MS, as well as recent, relevant data regarding their effectiveness and safety
• Incorporate recommendations and expert opinions regarding timely and effective monitoring of MS activity and progression
• Improve communication and coordination among multidisciplinary clinicians who manage patients with MS
• Apply components of the comprehensive care model into the management of patients with MS

TARGET AUDIENCE

This activity was developed for neurologists, nursing professionals, and other members of the healthcare team who care for patients with MS.

FACULTY

Patricia K. Coyle, MD
Director, MS Comprehensive Care Center
Professor of Neurology
Stony Brook University

Fred D. Lublin, M.D., FAAN, FANA
Saunders Family Professor of Neurology
Director, The Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Icahn School of Medicine at Mount Sinai

Patricia Melville, RN, MSN, NP-C, MSCN
Clinical Instructor
Department of Neurology
SUNY at Stony Brook

ACCREDITATION AND CREDIT INFORMATION

In support of improving patient care, this activity has been planned and implemented by the Consortium of Multiple Sclerosis Centers (CMSC) and The France Foundation. CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CREDIT

The CMSC designates this activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSE CREDIT

The CMSC designates this enduring material for 3.0 contact hours of continuing education (None in the area of pharmacology).

CERTIFICATE OF COMPLETION

A Certificate of Completion may be given upon completion of course requirements enabling you to register your credit with the appropriate licensing boards or associations. You may apply for other accreditations using the procedure established by the specific organization.

OFF LABEL STATEMENT

The Consortium of Multiple Sclerosis Centers (CMSC) and The France Foundation (TFF) require CME/CE faculty (speakers) to disclose when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. CMSC and TFF do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

DISCLOSURES

The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

The following faculty report that they have relevant financial relationships to disclose:

• Patricia K. Coyle, MD, has served as a consultant for AbbVie, Accordant, Acorda, Bayer, Biogen, Celgene, Genentech/Roche, Novartis, Sanofi Genzyme, Serono and Teva. She has done contract research for Actelion, Alkermes, Genentech/Roche, MedDay, NINDS and Novartis.
• Fred D. Lublin, MD, FAAN, FANA, has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Abbvie, Acorda, Actelion, Apitope, Atara Biotherapeutics, Bayer HealthCare Pharmaceuticals, Biogen Idec, EMD Serono, Forward Pharma, Innate Immunotherapeutics, Mapi Pharma, MedDay, MedImmune , Novartis, Polpharma, Receptos/Celgene, Regeneron, Roche/Genentech, Sanofi/Genzyme, Teva, TG Therapeutics and Toyama. He has received research funding from Actelion, NMSS, Novartis Pharmaceuticals Corp, Teva Neuroscience, Inc. and Transparency Life Sciences.
• Patricia Melville, RN, MSN, NP-C, MSCN, has served as a consultant for Biogen, Genentech and Genzyme. She has served on a speakers bureau for Biogen, Genentech, Genzyme, Novartis and EMD Serono.

METHOD OF PARTICIPATION / HOW TO RECEIVE CREDIT

1. There are no fees for participating in and receiving credit for this activity.
2. Review the activity objectives and CME/CE information.
3. Complete the CME/CE activity
4. Complete the online posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
5. Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
6. Credit documentation/reporting, your CME/CE certificate will be available for download.

CLICK HERE TO VIEW TECHNICAL REQUIREMENTS